IMMUNOVANT, INC. Basic Shares Outstanding (Weighted Average)
IMMUNOVANT, INC. (IMVT) reported Basic Shares Outstanding (Weighted Average) of 205.55 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-06
- IMMUNOVANT, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 205.55M shares, a 20.29% increase year-over-year.
- IMMUNOVANT, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 203.44M shares, a 22.10% increase year-over-year.
- IMMUNOVANT, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 181.51M shares, a 23.54% increase year-over-year.
- IMMUNOVANT, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 173.64M shares, a 18.55% increase year-over-year.
- IMMUNOVANT, INC. weighted average number of shares outstanding, basic for fiscal 2026 was 182.42M shares, a 20.35% increase from fiscal 2025.
- IMMUNOVANT, INC. weighted average number of shares outstanding, basic for fiscal 2025 was 151.57M shares, a 9.76% increase from fiscal 2024.
- IMMUNOVANT, INC. weighted average number of shares outstanding, basic for fiscal 2024 was 138.10M shares, a 12.21% increase from fiscal 2023.
- IMMUNOVANT, INC. weighted average number of shares outstanding, basic for fiscal 2023 was 123.08M shares, a 12.21% increase from fiscal 2022.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 205.55M shares 10-Q · filed 2026-08-06 | 204.49M shares derived: average of 2 quarters · filed 2026-08-06 | 196.83M shares derived: average of 3 quarters · filed 2026-08-06 | 191.04M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 203.44M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | 192.48M shares derived: average of 2 quarters · filed 2026-05-20 | 186.20M shares derived: average of 3 quarters · filed 2026-05-20 | 182.42M shares 10-K · filed 2026-05-20 |
| 2025-12-31 | 181.51M shares 10-Q · filed 2026-02-06 | 177.58M shares derived: average of 2 quarters · filed 2026-02-06 | 175.41M shares 10-Q · filed 2026-02-06 | 173.16M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-09-30 | 173.64M shares 10-Q · filed 2025-11-10 | 172.30M shares 10-Q · filed 2025-11-10 | 170.38M shares derived: average of 3 quarters · filed 2026-08-06 | 164.51M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | 170.87M shares 10-Q · filed 2026-08-06 | 168.74M shares derived: average of 2 quarters · filed 2026-08-06 | 161.47M shares derived: average of 3 quarters · filed 2026-08-06 | 157.72M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | 166.61M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | 156.77M shares derived: average of 2 quarters · filed 2026-05-20 | 153.33M shares derived: average of 3 quarters · filed 2026-05-20 | 151.57M shares 10-K · filed 2026-05-20 |
| 2024-12-31 | 146.92M shares 10-Q · filed 2026-02-06 | 146.70M shares derived: average of 2 quarters · filed 2026-02-06 | 146.56M shares 10-Q · filed 2026-02-06 | 146.29M shares derived: average of 4 quarters · filed 2026-05-20 |
| 2024-09-30 | 146.47M shares 10-Q · filed 2025-11-10 | 146.31M shares 10-Q · filed 2025-11-10 | 146.08M shares derived: average of 3 quarters · filed 2026-05-20 | 145.69M shares derived: average of 4 quarters · filed 2026-05-20 |
| 2024-06-30 | 146.09M shares 10-Q · filed 2025-08-11 | 145.88M shares derived: average of 2 quarters · filed 2026-05-20 | 145.43M shares derived: average of 3 quarters · filed 2026-05-20 | 141.86M shares derived: average of 4 quarters · filed 2026-05-20 |
| 2024-03-31 | 145.67M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | 145.10M shares derived: average of 2 quarters · filed 2026-05-20 | 140.45M shares derived: average of 3 quarters · filed 2026-05-20 | 138.10M shares 10-K · filed 2026-05-20 |
| 2023-12-31 | 144.52M shares 10-Q · filed 2025-02-06 | 137.84M shares derived: average of 2 quarters · filed 2025-02-06 | 135.58M shares 10-Q · filed 2025-02-06 | 134.12M shares derived: average of 4 quarters · filed 2025-05-29 |
| 2023-09-30 | 131.16M shares 10-Q · filed 2024-11-07 | 130.87M shares 10-Q · filed 2024-11-07 | 130.65M shares derived: average of 3 quarters · filed 2025-05-29 | 130.13M shares derived: average of 4 quarters · filed 2025-05-29 |
| 2023-06-30 | 130.50M shares 10-Q · filed 2024-08-06 | 130.40M shares derived: average of 2 quarters · filed 2025-05-29 | 129.79M shares derived: average of 3 quarters · filed 2025-05-29 | 126.49M shares derived: average of 4 quarters · filed 2025-05-29 |
| 2023-03-31 | 130.31M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | 129.44M shares derived: average of 2 quarters · filed 2025-05-29 | 125.15M shares derived: average of 3 quarters · filed 2025-05-29 | 123.08M shares 10-K · filed 2025-05-29 |
| 2022-12-31 | 128.57M shares 10-Q · filed 2024-02-12 | 122.57M shares derived: average of 2 quarters · filed 2024-02-12 | 120.67M shares 10-Q · filed 2024-02-12 | 119.52M shares derived: average of 4 quarters · filed 2024-02-12 |
| 2022-09-30 | 116.57M shares 10-Q · filed 2023-11-09 | 116.63M shares 10-Q · filed 2023-11-09 | 116.50M shares derived: average of 3 quarters · filed 2023-11-09 | 116.13M shares derived: average of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | 116.56M shares 10-Q · filed 2023-08-10 | 116.47M shares derived: average of 2 quarters · filed 2023-08-10 | 115.99M shares derived: average of 3 quarters · filed 2023-08-10 | 114.26M shares derived: average of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | 116.37M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-05-22 | 115.70M shares derived: average of 2 quarters · filed 2023-05-22 | 113.49M shares derived: average of 3 quarters · filed 2023-05-22 | 109.68M shares 10-K · filed 2023-05-22 |
| 2021-12-31 | 115.03M shares 10-Q · filed 2023-02-03 | 112.05M shares derived: average of 2 quarters · filed 2023-02-03 | 107.45M shares 10-Q · filed 2023-02-03 | 104.97M shares derived: average of 4 quarters · filed 2023-02-03 |
| 2021-09-30 | 109.08M shares 10-Q · filed 2022-11-04 | 103.56M shares 10-Q · filed 2022-11-04 | 101.61M shares derived: average of 3 quarters · filed 2022-11-04 | 100.69M shares derived: average of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | 97.98M shares 10-Q · filed 2022-08-05 | 97.88M shares derived: average of 2 quarters · filed 2022-08-05 | 97.89M shares derived: average of 3 quarters · filed 2022-08-05 | 94.51M shares derived: average of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | 97.79M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-08 | 97.85M shares derived: average of 2 quarters · filed 2022-06-08 | 93.35M shares derived: average of 3 quarters · filed 2022-06-08 | 87.76M shares 10-K · filed 2022-06-08 |
| 2020-12-31 | 97.92M shares 10-Q · filed 2022-02-04 | 91.14M shares derived: average of 2 quarters · filed 2022-02-04 | 84.41M shares 10-Q · filed 2022-02-04 | |
| 2020-09-30 | 84.35M shares 10-Q · filed 2021-11-05 | 77.62M shares 10-Q · filed 2021-11-05 | ||
| 2020-06-30 | 70.82M shares 10-Q · filed 2021-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |